Intelligence Β· Drug directory
EMA-Approved Drugs Directory
European Medicines Agency approved medicines with EPAR-derived status, INN profiles, and competitive intelligence links.
Quick answer
EMA-approved drugs: NovaPharmaNews tracks 931 pharmaceutical drugs in this segment. European Medicines Agency approved medicines with EPAR-derived status, INN profiles, and competitive intelligence links.
-
pertussis vaccine (recombinant, acellular, component, adsorbed)
VACPERTAGEN
J07AJ02 -
phenylephrine
OMIDRIA
S01 -
piflufolastat (18f)
PYLCLARI
V09 -
piperaquine tetraphosphate
EURARTESIM
P01BF05 -
pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
PREVENAR 13
J07AL02 -
pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)
PREVENAR 20 (PREVIOUSLY APEXXNAR)
J07AL02 -
pneumococcal polysaccharide conjugate vaccine (21-valent)
CAPVAXIVE
J07AL02 -
pneumococcal polysaccharide conjugate vaccine (adsorbed)
SYNFLORIX
J07AL52 -
polatuzumab vedotin
POLIVY
L01FX14 -
polihexanide
AKANTIOR
S01AX24 -
ponatinib
ICLUSIG Lacuna Pharma Pty Ltd
L01EA05 -
prasugrel
PRASUGREL LUPIN
B01AC22 -
propranolol
APO-PROPRANOLOL Alphapharm Pty Ltd
C07AA05 -
quadrivalent influenza vaccine (recombinant, prepared in cell culture)
SUPEMTEK TETRA (PREVIOUSLY SUPEMTEK)
J07BB02 -
quizartinib
VANFLYTA
L01EX11 -
radium ra223 dichloride
XOFIGO
V10XX03 -
raltegravir
ISENTRESS Merck KGaA, Darmstadt, Germany
J05AJ01 -
ravulizumab
ULTOMIRIS Lacuna Pharma Pty Ltd
L04AA43 -
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e
AREXVY
J07BX05 -
relatlimab
OPDUALAG
L01FY02 -
remimazolam
BYFAVO
N05CD14 -
respiratory syncytial virus vaccine (bivalent, recombinant)
ABRYSVO
J07BX05 -
retifanlimab
ZYNYZ
L01FF10 -
rezafungin
REZZAYO
J02AX08
Frequently asked questions
How many ema approved drugs are listed?
931 drug profiles match this regulatory segment in our published index.
Where does approval data come from?
Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.